Irbesartan
Unchecked
Irbesartan
Avapro
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
150 mg PO once daily; titrate to 300 mg if needed
Preparations
75, 150, 300 mg tablets
US FDA Max
300 mg/d
Pharmacology
Routes
Oral
Onset
BP effect within 1-2 weeks
Duration
24 hours
Half-life
11-15 hours[1]
Bioavailability
60-80% (oral; not significantly affected by food)[1]
Pregnancy
Contraindicated in pregnancy (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection[1]
Legal status
Rx-only in US
Purported mechanism
Irbesartan is a selective AT1 angiotensin-II receptor antagonist; blocking AT1 produces vasodilation, decreased aldosterone, and reduced sodium retention without the bradykinin accumulation that drives ACE-inhibitor cough.0 CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Avapro (irbesartan), Sanofi-Aventis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020757s075lbl.pdf